See full images - free registration
Continue with Google - no registration! or register with email

Why register? Just to keep bots out of our catalog. Your email stays private - we will never share it or send you anything uninvited. We guarantee you that!

Drachm - Orodes I

Issuer Parthian Empire
Year 80 BC - 75 BC
Type Log in to see details
Value Drachm (1)
Currency Log in to see details
Composition Log in to see details
Weight Log in to see details
Diameter Log in to see details
Thickness Log in to see details
Shape Log in to see details
Technique Log in to see details
Orientation Log in to see details
Engraver(s) Log in to see details
In circulation to Log in to see details
Reference(s) Log in to see details
Obverse description Log in to see details
Obverse script Log in to see details
Obverse lettering Log in to see details
Reverse description Arsaces I, the dynastic founder, shown seated to the right on a throne or omphalos, holding a bow in his right hand, rendered in the standard Parthian archer type. The figure is depicted in a frontal or three-quarter pose with drapery indicated by incised lines. The encircling Greek legend fills the field on both sides and below the central device, arranged in multiple lines. The style is characteristic of the late second to early first century BC Parthian mint production, with the legend crowding the available flan space in the manner typical of Sellwood 34 issues.
Reverse script Log in to see details
Reverse lettering Log in to see details
Edge Log in to see details
Mint Log in to see details
Mintage ND (80 BC - 75 BC)
Additional information

Orodes I ruled during one of the Parthian dynasty's most turbulent succession crises, seizing power after the overthrow of Gotarzes I and reigning for only a few years before himself being deposed. Sellwood type 34 belongs to a compressed window of output, and the political instability of the period is reflected in the relative inconsistency of dies across the series.

The mint attributions for this type remain contested among specialists, with Ecbatana the most commonly proposed but not universally accepted.

YOU MAY ALSO LIKE